Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The FOLFOX6 regimen is a standard chemotherapy regimen for the treatment of patients with
colorectal cancer and other gastrointestinal cancers. Tivozanib (AV-951) is a targeted
anti-angiogenesis agent that has demonstrated acceptable tolerability in a phase I clinical
trial. This study is designed to test the hypothesis that tivozanib (AV-951) can be combined
with standard FOLFOX6 chemotherapy for the treatment of patients with colorectal and other
gastrointestinal cancers. The purpose of this study is to determine the maximum dose of
tivozanib (AV-951) that can be safely combined with FOLFOX6 chemotherapy, and to evaluate the
safety profile, tolerability, and pharmacokinetics of this combination.